Anzeige
Mehr »
Login
Dienstag, 21.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Aktienchance des Jahres! Ihre Chance auf explosive Gewinne!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
455 Leser
Artikel bewerten:
(2)

Parker-Hannifin Corporation: Parker Announces Retirement of Executive Chairman Thomas L. Williams and Election of Jennifer A. Parmentier as Chairman of the Board

Finanznachrichten News

CLEVELAND, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Parker Hannifin Corporation (NYSE: PH), the global leader in motion and control technologies, today announced that its Board of Directors has elected Jennifer A. Parmentier, currently Chief Executive Officer and a Director, as Chairman of the Board, effective January 1, 2024. Ms. Parmentier will succeed Thomas L. Williams, Executive Chairman, who will retire on December 31, 2023, as previously announced.

"We congratulate and look forward to working with Jenny in her expanded role as Chairman of the Board," said James L. Wainscott, Parker's independent Lead Director. "Our dual leadership structure, consisting of both a Chairman of the Board and a separate and independent Lead Director, continues to effectively serve shareholders. We thank Tom for his many years of exemplary service leading our Board and leading the company through a period of unprecedented performance and transformation in which we delivered substantial shareholder returns."

"Tom's world-class leadership and achievements set Parker on a remarkably positive trajectory," said Parmentier. "It is an honor to succeed him as Chairman of the Board, as it was to succeed him as CEO and to have the opportunity to build on that legacy of leadership and success and take our performance to the next level. I appreciate the trust of our Board, our senior leadership team, and our global team members as we look ahead to Parker's promising future."

Ms. Parmentier became Chief Executive Officer on January 1, 2023. She previously served as Chief Operating Officer starting in 2021, with responsibility for all of Parker's operating groups. Ms. Parmentier was Vice President and President - Motion Systems Group from 2019 to 2021 and Vice President and President - Engineered Materials Group from 2015 to 2019, where she was responsible for all financial and strategic aspects of their global operations. Prior to those roles, since joining Parker in 2008, she held a variety of operational roles including General Manager of the Sporlan Division in the Instrumentation Group, and General Manager of the Hose Products Division in the Fluid Connectors Group.

Mr. Williams served as Chief Executive Officer from February 1, 2015, through December 31, 2022 and has served as Chairman of the Board since January 1, 2016. He joined Parker in 2003 and demonstrated successful leadership in two operating groups, first as Vice President of Operations for the Hydraulics Group and then as President of the Instrumentation Group. He was named Operating Officer in 2006, with responsibility for Parker's Aerospace, Engineered Materials, Filtration, Instrumentation and Asia Pacific groups.

About Parker Hannifin
Parker Hannifin is a Fortune 250 global leader in motion and control technologies. For more than a century the company has been enabling engineering breakthroughs that lead to a better tomorrow. Learn more at www.parker.com or @parkerhannifin.com.

###

 
Tom WilliamsJenny Parmentier
© 2023 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.